ID: h-4a4a2713
Hypothesis
Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization
Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
Mitochondrial Pyruvate Carrier Inhibition to Force Metabolic Reprogramming Toward Ketone Utilization
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["MPC1/MPC2 Inhibition<br/>Mitochondrial Pyruvate Carrier Blocked"]
B["Glycolytic Shift<br/>Lactate丰度增加"]
C["Astrocyte-Neuron<br/>Lactate Shuttle Enhanced"]
D["Metabolic Reprogramming<br/>Warburg-like State"]
E["Neuronal Energetic<br/>Vulnerability Reduced"]
F["Neurodegeneration<br/>Metabolic Resilience"]
G["MPC Inhibition<br/>as Metabolic Reprogramming Tool"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"forces"| D
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
MPC1 mRNA upregulation in human AD brain (computational: GTEx Brain Tissue Expression Database)
Supports
Pharmaceutical MPC inhibition protects against ischemia-reperfusion injury by activating protective metabolic pathways
Supports
Forcing ketone body utilization activates BDNF signaling and enhances mitochondrial biogenesis
Supports
Cancer metabolism literature confirms MPC inhibition shifts cells toward glutamine and fatty acid oxidation
Contradicts
MPC1 mRNA upregulation is computational annotation, not peer-reviewed validation - foundational claim lacks rigorous support
Contradicts
MPC inhibition reduces neuronal firing rates in vitro - neurons are highly dependent on glucose-derived pyruvate oxidation
Contradicts
Forcing ketone utilization in already-metabolically-compromised neurons risks acute energy failure
Contradicts
Cancer metabolism literature does not translate directly - adult neurons are post-mitotic with different metabolic priorities
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MPC1
No curated PDB or AlphaFold mapping for MPC1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for MPC1/MPC2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MPC1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↗
Rising
7d Momentum
▲ 1.5%
Volatility
Low
0.0104
Events (7d)
3
Price History
▲31.2%💾 Resource Usage
LLM Tokens
38,010
$0.1140
Total Cost
$0.1140
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6J mice on a high‑fat diet receive daily intraperitoneal injections of the MPC inhibitor MSDC‑0160 (10 mg/kg) for 14 days THEN plasma β‑hydroxybutyrate levels will rise by at least 50 % compa | ≥50% increase in plasma β‑hydroxybutyrate (βHB) relative to vehicle‑treated mice. | — no observation — | pending | 0.70 |
| IF primary human hepatocytes cultured in Williams’ E medium supplemented with 1 mM octanoate are treated with 10 µM MSDC‑0160 for 48 h THEN extracellular ketone bodies (acacetate + βHB) increase by ≥2 | ≥2‑fold increase in extracellular ketone bodies; ≥30% reduction in glucose consumption. | — no observation — | pending | 0.60 |
🔮 Falsifiable Predictions (2)
pendingconf 70%
IF C57BL/6J mice on a high‑fat diet receive daily intraperitoneal injections of the MPC inhibitor MSDC‑0160 (10 mg/kg) for 14 days THEN plasma β‑hydroxybutyrate levels will rise by at least 50 % compared to vehicle‑treated controls within 4 h after the final injection.
Predicted outcome: ≥50% increase in plasma β‑hydroxybutyrate (βHB) relative to vehicle‑treated mice.
Falsification: Plasma βHB does not increase (≤10% change) or decreases relative to vehicle control.
pendingconf 60%
IF primary human hepatocytes cultured in Williams’ E medium supplemented with 1 mM octanoate are treated with 10 µM MSDC‑0160 for 48 h THEN extracellular ketone bodies (acacetate + βHB) increase by ≥2‑fold and glucose consumption decreases by ≥30 % relative to DMSO‑treated controls.
Predicted outcome: ≥2‑fold increase in extracellular ketone bodies; ≥30% reduction in glucose consumption.
Falsification: Extracellular ketone bodies show <1.2‑fold change and/or glucose consumption does not decrease by at least 30%.
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.